Korro Bio, Inc. Common Stock (KRRO) Stock Price

KRROStock

$13.73−34.78%52W

Market Cap$202.18M

P/E—

PEG Ratio—

Div yield—

Beta3.10

KRRO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)5.09%

Price vs S&P 500 (4W)21.42%

VGM Score36.15

Book Value / Share (Quarterly)$7.02

P/TBV (Annual)4.43x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-23.12%

Cash Flow / Share (Quarterly)$-4.64

Price vs S&P 500 (YTD)51.21%

Net Profit Margin (TTM)-1834.48%

EPS (TTM)$-10.00

10-Day Avg Trading Volume0.08M

EPS Excl Extra (TTM)$-10.00

Revenue Growth (5Y)-26.07%

EPS (Annual)$-12.48

ROI (Annual)-227.96%

Gross Margin (Annual)44.73%

Net Profit Margin (5Y Avg)-1161.48%

Cash / Share (Quarterly)$7.82

Revenue Growth QoQ (YoY)-43.11%

ROA (Last FY)-103.31%

Revenue Growth TTM (YoY)-62.08%

EBITD / Share (TTM)$-8.96

ROE (5Y Avg)-87.08%

Operating Margin (TTM)-1906.37%

Cash Flow / Share (Annual)$-8.40

P/B Ratio1.90x

P/B Ratio (Quarterly)1.84x

Net Income / Employee (Annual)$-2,021,700

EV / Revenue (TTM)26.72x

Net Interest Coverage (TTM)-57.71x

ROA (TTM)-68.57%

EPS Incl Extra (Annual)$-12.48

Current Ratio (Annual)6.90x

Quick Ratio (Quarterly)9.11x

3-Month Avg Trading Volume0.16M

52-Week Price Return-34.78%

Revenue / Employee (TTM)$41,100

Tangible BV / Share (Quarterly)$49.74

P/S Ratio (Annual)30.62x

Asset Turnover (Annual)0.06x

52-Week High$55.89

Operating Margin (5Y Avg)-1270.34%

EPS Excl Extra (Annual)$-12.48

CapEx CAGR (5Y)-40.02%

Tangible BV CAGR (5Y)32.33%

26-Week Price Return16.33%

Quick Ratio (Annual)6.38x

13-Week Price Return16.70%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.55x

Enterprise Value$170.80M

Revenue / Share Growth (5Y)-6.05%

Asset Turnover (TTM)0.04x

Book Value / Share Growth (5Y)29.09%

Revenue / Employee (Annual)$110,200

Pretax Margin (Annual)-1824.52%

Cash / Share (Annual)$7.98

3-Month Return Std Dev85.52%

Net Income / Employee (TTM)$-1,838,700

ROE (Last FY)-227.96%

Net Interest Coverage (Annual)-36.96x

EPS Basic Excl Extra (Annual)$-12.48

Receivables Turnover (TTM)4.37x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-10.00

Receivables Turnover (Annual)4.80x

ROI (TTM)-114.26%

P/S Ratio (TTM)30.62x

Pretax Margin (5Y Avg)-1158.23%

Revenue / Share (Annual)$0.68

Tangible BV / Share (Annual)$98.12

Price vs S&P 500 (52W)-53.09%

Year-to-Date Return63.17%

5-Day Price Return-1.13%

EPS Normalized (Annual)$-12.48

ROA (5Y Avg)-54.56%

Net Profit Margin (Annual)-1834.48%

Month-to-Date Return26.04%

Cash Flow / Share (TTM)$-79.22

EBITD / Share (Annual)$-12.51

Operating Margin (Annual)-1906.37%

LT Debt / Equity (Annual)0.06x

ROI (5Y Avg)-87.08%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-10.00

P/TBV (Quarterly)8.34x

P/B Ratio (Annual)1.47x

Pretax Margin (TTM)-1824.52%

Book Value / Share (Annual)$5.46

Price vs S&P 500 (13W)13.90%

Beta3.10x

P/FCF (Annual)5.90x

Revenue / Share (TTM)$0.14

ROE (TTM)-114.26%

52-Week Low$5.20

vGradeD

gGradeF

mGradeC

vgmGradeD

KRRO Earnings Surprise History

Q2 25-2.74est. -2.59

Q3 25-1.92est. -2.68

Q4 25-1.65est. -2.14

Q1 26-1.69est. -1.98

Q2 26-1.07est. -1.28

KRRO Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.06

4.13

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
KRROKorro Bio, Inc. Common Stock	D	F	C	$13.73
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Korro Bio, Inc. Common Stock

Korro Bio is a biopharmaceutical company developing RNA-editing genetic medicines to treat rare and prevalent diseases. The company's proprietary platform leverages the body's natural RNA editing process to create precise, transient single-base edits with greater reversibility than traditional DNA-editing approaches. This differentiated technology positions Korro Bio to address significant unmet medical needs in genetic medicine with enhanced precision and tunability.